Capstone Therapeutics Announces That Its Joint Venture,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc., Has Closed a Series B-1 Preferred Stock Offering

TEMPE, Ariz., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“ JV ”) announced today that the JV’s Series B-1 preferred stock offering totaling $1,012,000 closed on August 25, 2016. Individual accredited investors and management participated in the financing.   Evolution Venture Partners, a NY-based investment bank, has been engaged to advise the JV on corporate finance matters.

This closing of the Series B-1 preferred stock offering resulted in the issuance of 94,537 shares of preferred stock, convertible to an equal number of the JV’s common shares at the election of the holders, and warrants to purchase an additional 33,088 shares of JV Series B-1 preferred stock, at an exercise price of $10.70 per share. The preferred stock issued at closing represents 7.8% of the post-closing common stock of the JV, on an as-converted basis and suggests an approximate $13.7 million post-money valuation. Following this Series B-1 closing, Capstone owns 59.3% of the JV.

Dennis I. Goldberg, President of LipimetiX Development, Inc. stated, “We appreciate the confidence shown by this investor group in allowing us to advance the development of AEM-28-14.  This molecule has shown profound and rapid reduction of both cholesterol and triglycerides in multiple validated preclinical models.  In addition, the molecule continues to be evaluated under material transfer agreement by pharma, lending credibility to our program and to our efforts to finance further development.”   The JV’s development goals are to conduct Phase 1a, 1b, and 2a human clinical trials with AEM-28-14 (and/or analogs) to show an acceptable safety profile and efficacy signals in indications involving hypercholesterolemia and hypertriglyceridemia.

Raising additional funds in the JV may or may not occur, and additional funds raised, if any, may not be sufficient for the JV to reach its development goals or create shareholder value, and may also contain terms or conditions that could significantly impact the Company’s investment value or ownership position.

Chimeric Apolipoprotein E Mimetic Peptides

Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body.  Apo E is essential for the normal metabolism of cholesterol and triglycerides.  After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream.  Apo E targets cholesterol and triglyceride-rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood.  Defective metabolism of triglyceride-rich lipoprotein remnants plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to diseases of the coronary, cerebral and peripheral arteries, and to microvascular disease in the kidneys.  This can cause heart attack, stroke, loss of limbs and kidney failure, the most common causes of morbidity and mortality in diabetics.

The University of Alabama at Birmingham (“UAB”) scientists patented the first chimeric Apo E mimetic peptide in 1999, reducing the 299 amino acid native Apo E into a 28 amino acid, dual domain peptide that can be delivered therapeutically.  One domain inserts into a lipoprotein surface and the second domain binds to the Apo E receptors in the liver.  In 2010, our JV’s founding scientist, Dr. Dennis Goldberg, obtained worldwide right to patents for Apo E mimetic peptides from the UAB Research Foundation (“UABRF”).  The JV has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for AEM-28 and its analogs.

The JV has continued research in to a new generation of chimeric Apo E peptides and has discovered AEM-28-14, resulting in a provisional patent filing in 2015.  AEM-28-14 was found to be more potent (as tested in multiple animal models) than the parent molecule, AEM-28.  Currently the JV intends to concentrate its development efforts on AEM-28-14.

Subject to continued favorable study results and funding availability, the JV may pursue regulatory approval of AEM-28-14 as treatment for Homozygous Familial Hypercholesterolemia and other orphan indications in hypertriglyceridemia.  The JV may, in the future, possibly explore additional indications for its family of Apo E mimetic peptides including Acute Coronary Syndrome, Peripheral Artery Disease and other vascular complications associated with Type 2 Diabetes.

About Capstone Therapeutics

Capstone Therapeutics is a biotechnology company committed to developing novel therapeutic peptides aimed at helping patients with under-served medical conditions.  The Company is focused on development and commercialization of Chimeric Apo E Mimetic Peptides through the LipimetiX Development, Inc. joint venture and currently owns 59.3% of the joint venture.

Capstone’s corporate headquarters are in Tempe, Arizona.  For more information, please visit the Company's website:  www.capstonethx.com .  For more information on LipimetiX Development, please visit the JV’s website:  www.lipimetix.com .

Statements in this press release or otherwise attributable to Capstone regarding our business that are not historical facts are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results.  These risks include the factors discussed in our Form 10-K for the fiscal year ended December 31, 2015, and other documents we file with the U.S. Securities and Exchange Commission.

Editor’s Note:  This press release is also available under the Investors section of the Company’s website at www.capstonethx.com .

FOR FURTHER INFORMATION: Investor Relations (602) 286-5250 investorinquiries@capstonethx.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 136

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
Shenzhen Three-Way Summit Puts Stability to the Test

Updated Category News Views 191

Three nuclear powers sharing a room in Shenzhen is the sort of headline that makes every risk desk sit upright, even when the paperwork remains thin. CGTN reports that Chinese President Xi Jinping, Russian President Vladimir Putin and U.S. President Donald Trump met on November 19, 2026, in an unprecedented trilateral summit and issued a Declaration toward Peace. That is...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 96

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 79

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
Lieda Shadwick’s Career Education Work Earns 2026 Honor

Updated Category News Views 76

Twenty-six years in classrooms is not the sort of accomplishment that needs fireworks to carry weight. Lieda A. Shadwick’s recognition as The Inner Circle’s 2026 Educator of the Year points to a career built around a stubbornly important idea: students need more than academic vocabulary if they are going to navigate work, leadership, and business with any confidence....

Continue Reading
Ductless Mini-Splits Put HVAC Efficiency Into Focus

Updated Category News Views 46

Ductless mini-splits have slipped from contractor jargon into a serious conversation about how homes and smaller buildings are heated and cooled. That is the worthwhile backdrop for a HelloNation article featuring HVAC expert Natasha Adams. The source notes are lean—really lean—and do not spell out her specific guidance, product comparisons, efficiency figures,...

Continue Reading
Fermi Board Fight Tests Texas Governance Standards Again

Updated Category News Views 60

A boardroom rulebook is supposed to restrain power, not become a trapdoor under shareholders’ feet. That is the ugly governance question hanging over Fermi after the Texas Business Court dismissed Toby Neugebauer’s challenge to the company’s 70% supermajority bylaw. Neugebauer, Fermi’s co-founder and largest shareholder, says he will appeal. Frankly, he has every...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 134

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 101

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 105

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Investigation into iTeos Therapeutics Acquisition

Updated Category News Views 182

Investigation Overview of iTeos Therapeutics, Inc. Rowley Law PLLC is currently delving into possible violations of securities laws involving iTeos Therapeutics, Inc. (NASDAQ: ITOS) and its board of directors regarding the proposed acquisition by Concentra Biosciences, LLC. This acquisition aims to provide stockholders with $10.047 for each share they hold, accompanied by...

Continue Reading
Ares Management Joins S&P 500; Changes in SmallCap 600

Updated Category News Views 483

Ares Management Join the S&P 500 In an exciting development for investors, Ares Management (NYSE: ARES) will be joining the S&P 500 index shortly. This news comes as Kellanova (NYSE: K) has announced its acquisition by Mars Inc., which has precipitated the need for these changes in the index. Ares Management is making a mark in the financial sector and its inclusion...

Continue Reading
Berkshire Hathaway's Q3 Earnings Report: Key Insights Revealed

Updated Category News Views 113

Berkshire Hathaway's Underwhelming Third Quarter Performance Berkshire Hathaway's recent third-quarter earnings report has raised eyebrows as the results fell short of analyst predictions. The earnings per share (EPS) came in at $4.68, whereas consensus estimates were looking for $4.89. Analysts have pointed to several factors influencing this underperformance. Insurance...

Continue Reading
Multitude SE Reports 34.5% EBIT Growth in 2024

Updated Category News Views 101

Multitude SE Reports Strong Growth in 2024 Key takeaways: The company continues to perform well, maintaining a robust cash position. Group revenue has risen by 17.0%, reaching EUR 128.8 million. All business units are reporting at least double-digit revenue growth. On track to meet EBIT guidance of EUR 67.5 million (+50%) for 2024. Multitude SE, a leading European FinTech...

Continue Reading
Discover How Cboe Global Markets Has Grown Over a Decade

Updated Category News Views 241

Understanding the Growth of Cboe Global Markets Cboe Global Markets has displayed remarkable performance in the stock market over the past decade. Specifically, the company has outperformed the market by an average of 2.96% annually, resulting in a substantial annual return of approximately 14.72%. Presently, its market capitalization stands at around $26.52 billion,...

Continue Reading